Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ADP-A2M4CD8 |
| Trade Name | |
| Synonyms | Uzatresgene autoleucel|MAGE-A4 SPEAR CD8alpha T-cells|uza-cel |
| Drug Descriptions |
ADP-A2M4CD8 comprises autologous T-cells engineered to express a CD8alpha co-receptor and a T-cell receptor (TCR) targeting MAGE-A4, which potentially induces antitumor activity (J Clin Oncol 41, 2023 (suppl 6; abstr 517)). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C162804 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ADP-A2M4CD8 | ADP-A2M4CD8 | 0 | 1 |
| ADP-A2M4CD8 + Nivolumab | ADP-A2M4CD8 Nivolumab | 0 | 0 |